ZYDUSLIFEZydus Lifesciences

₹971.7-0.95%

Market Cap

₹98,057.50 Cr

Stock P/E

21.45

ROCE

26.06%

ROE

21.08%

Book Value

₹252.82

Financials

YoY Net Sales

EPS Growth

Operating Margin

No recent news available for this stock.

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

POSITIVES

•
End FY25 on a strong note with highest-ever operating profit and margins.
•
Full-year revenue growth and margin expansion; EBITDA growth; strong profitability.

NEGATIVES

•
Mirabegron litigation could extend; management maintains sales guidance for now.
•
US Revlimid pricing pressure and higher R&D spend may depress FY26 margins; guidance anchors around single-digit US growth.

Peer comparison data is not available for this stock.